End-of-day quote
Other stock markets
|
||
- USD | - |
05-21 | Lineage Cell Therapeutics, Inc. Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium | CI |
05-09 | Transcript : Lineage Cell Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 |
Sales 2024 * | 12.22M 965M | Sales 2025 * | 5.87M 463M | Capitalization | 173M 13.62B |
---|---|---|---|---|---|
Net income 2024 * | -29M -2.29B | Net income 2025 * | -32M -2.53B | EV / Sales 2024 * | 14.1 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 29.4 x |
P/E ratio 2024 * |
-7.03
x | P/E ratio 2025 * |
-5.31
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.56% |
Latest transcript on BioTime, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Brian Culley
CEO | Chief Executive Officer | 53 | 16/09/18 |
Jill Howe
DFI | Director of Finance/CFO | 48 | 13/11/22 |
Chief Operating Officer | - | 31/12/09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Neal Bradsher
BRD | Director/Board Member | 58 | 30/06/09 |
Brian Culley
CEO | Chief Executive Officer | 53 | 16/09/18 |
Deborah Andrews
BRD | Director/Board Member | 66 | 10/04/14 |
1st Jan change | Capi. | |
---|---|---|
+38.36% | 52.73B | |
+39.33% | 39B | |
-8.63% | 38.52B | |
+25.46% | 30.38B | |
-11.17% | 26.39B | |
+11.44% | 26.08B | |
+45.09% | 14.15B | |
+32.93% | 12.6B | |
-5.30% | 11.51B |